Why the study?
Central antihypertensives were developed in response to the need to suppress sympathetic activity in the regulation of arterial hypertension.
Moxonidine is highlighted as an effective and safe treatment for hypertension driven by sympathetic hyperactivity, such as in obesity and metabolic syndrome.
May support central agents in sympathetic-driven hypertension with comorbidities; leaves open need for RCTs before practice change.
Primary (essential) hypertension includes about 90% of all cases of hypertension, and the treatment is symptomatic. As the response to the need for suppression of sympathetic activity in the regulation of hypertension, central antihypertensives have been developed, through central and peripheral adrenergic and non-adrenergic mechanisms, to affect the reduction of sympathetic nerve activity, inhibition of norepinephrine release, reduction of systemic vascular resistance, peripheral vasodilatation, reduction of heart rate and lowering of blood pressure. Moxonidine has been proven to be effective and safe, whether used as monotherapy or in combination in the treatment of hypertension in which sympathetic hyperactivity predominates, especially in patients with metabolic syndrome, obese patients, patients with prehypertension and stress induced hypertension with catecholamine hyperactivity
No takes yet. Share an insight, caveat, or question.
Pandrc et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: